Rare diseases: a challenge for medicine and public health.
作者信息
Fehr Angela, Prütz Franziska
机构信息
Robert Koch Institute, Berlin, Centre for International Health Protection (ZIG).
Robert Koch Institute, Berlin, Department of Epidemiology and Health Monitoring.
出版信息
J Health Monit. 2023 Dec 13;8(4):3-6. doi: 10.25646/11826. eCollection 2023 Dec.
Abstract
摘要
相似文献
1
Rare diseases: a challenge for medicine and public health.罕见病：医学与公共卫生面临的挑战。
J Health Monit. 2023 Dec 13;8(4):3-6. doi: 10.25646/11826. eCollection 2023 Dec.
2
The Ice Bucket Challenge: The public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseases.冰桶挑战：公共部门应做好准备，迅速推动罕见病医疗护理和研究体系的可持续发展。
Intractable Rare Dis Res. 2014 Aug;3(3):94-6. doi: 10.5582/irdr.2014.01015.
3
Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.通过实施精准公共卫生框架，改善罕见病的诊断和护理。
Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4.
4
Non-Communicable Diseases and Rare Diseases: A Current and Future Public Health Challenge within Pediatrics.非传染性疾病与罕见病：儿科学领域当前及未来的公共卫生挑战
Children (Basel). 2022 Sep 28;9(10):1491. doi: 10.3390/children9101491.
5
Optimizing Precision Medicine for Public Health.优化公共卫生领域的精准医学
Front Public Health. 2019 Mar 7;7:42. doi: 10.3389/fpubh.2019.00042. eCollection 2019.
6
Postgraduate and research programmes in Medicine and Public Health in Rwanda: an exciting experience about training of human resources for health in a limited resources country.卢旺达医学与公共卫生领域的研究生及研究项目：在一个资源有限的国家开展卫生人力资源培训的精彩经历。
Pan Afr Med J. 2016 Apr 8;23:171. doi: 10.11604/pamj.2016.23.171.8788. eCollection 2016.
7
Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public-private partnerships.罕见病和先天性代谢缺陷药物的研发：新型公私合作伙伴关系。
J Inherit Metab Dis. 2023 Sep;46(5):806-816. doi: 10.1002/jimd.12605. Epub 2023 Apr 1.
8
WHY THE RARE DISEASES BECOME TO BE A CHALLENGE FOR MEDICINE OF TODAY?为什么罕见病成为了当今医学的一项挑战？
Dev Period Med. 2015 Oct-Dec;19(4):401-2.
9
Metabolomics for Animal Models of Rare Human Diseases: An Expert Review and Lessons Learned.代谢组学在罕见人类疾病动物模型中的应用：专家综述与经验教训
OMICS. 2019 Jun;23(6):300-307. doi: 10.1089/omi.2019.0065. Epub 2019 May 23.
10
Living with a Rare Health Condition: The Influence of a Support Community and Public Stigma on Communication, Stress, and Available Support.与罕见健康状况共存：支持社区和公众耻辱感对沟通、压力及可得支持的影响
J Appl Commun Res. 2017;45(2):179-198. doi: 10.1080/00909882.2017.1288292. Epub 2017 Mar 22.
引用本文的文献
1
Exploring Recent Developments in the Manifestation, Diagnosis, and Treatment of Patients with Smith-Lemli-Opitz Syndrome: From Molecular Pathways to Clinical Innovations.探索史密斯-勒米-奥皮茨综合征患者的临床表现、诊断和治疗的最新进展：从分子途径到临床创新
Int J Mol Sci. 2025 Jul 11;26(14):6672. doi: 10.3390/ijms26146672.
2
Plant molecular farming: a promising frontier for orphan drug production.植物分子农业：孤儿药生产的一个有前景的前沿领域。
Biotechnol Lett. 2025 May 17;47(3):56. doi: 10.1007/s10529-025-03596-2.
3
When neuromuscular disorders become stars.当神经肌肉疾病成为明星。
J Neurol. 2025 Apr 2;272(4):305. doi: 10.1007/s00415-025-13058-4.
4
2024 VCP International Conference: Exploring multi-disciplinary approaches from basic science of valosin containing protein, an AAA+ ATPase protein, to the therapeutic advancement for VCP-associated multisystem proteinopathy.2024年VCP国际会议：探索从含缬酪肽蛋白（一种AAA+ ATP酶蛋白）的基础科学到VCP相关多系统蛋白病治疗进展的多学科方法。
Neurobiol Dis. 2025 Apr;207:106861. doi: 10.1016/j.nbd.2025.106861. Epub 2025 Mar 2.
5
Integrating Machine Learning-Based Approaches into the Design of ASO Therapies.将基于机器学习的方法整合到反义寡核苷酸疗法的设计中。
Genes (Basel). 2025 Feb 2;16(2):185. doi: 10.3390/genes16020185.
6
Global insight into rare disease and orphan drug definitions: a systematic literature review.对罕见病和孤儿药定义的全球洞察：一项系统的文献综述。
BMJ Open. 2025 Jan 25;15(1):e086527. doi: 10.1136/bmjopen-2024-086527.
本文引用的文献
1
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.194 个国家和 6 个地区的孤儿药可及性和未满足需求：一项基于内容分析的全球政策回顾。
Value Health. 2020 Dec;23(12):1580-1591. doi: 10.1016/j.jval.2020.06.020. Epub 2020 Oct 31.
2
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.估算罕见病的累计点患病率：对孤儿药数据库的分析。
Eur J Hum Genet. 2020 Feb;28(2):165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.
3
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.罕见病药物的可及性：35个国家的立法、法规及政策综合综述
PLoS One. 2015 Oct 9;10(10):e0140002. doi: 10.1371/journal.pone.0140002. eCollection 2015.
4
Networking for rare diseases: a necessity for Europe.罕见病网络建设：欧洲的一项必要举措。
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 Dec;50(12):1477-83. doi: 10.1007/s00103-007-0381-9.
5
The common problem of rare disease in general practice.全科医疗中罕见病的常见问题。
Med J Aust. 2006 Jul 17;185(2):82-3. doi: 10.5694/j.1326-5377.2006.tb00477.x.
6
Two decades of orphan product development.二十年的孤儿药产品研发。
Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919.
Zotero 插件